Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
TuHURA Biosciences, Inc.
Eli Lilly and Company
BioNTech SE
Astellas Pharma Inc
Ascendis Pharma A/S
Pfizer
Eikon Therapeutics
ModernaTX, Inc.
Verastem, Inc.
AstraZeneca
Eli Lilly and Company
Erasca, Inc.
Eli Lilly and Company
Novartis
Eli Lilly and Company
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Shenzhen Ionova Life Sciences Co., Ltd.
GI Innovation, Inc.
Eli Lilly and Company
PMV Pharmaceuticals, Inc
Merck Sharp & Dohme LLC
Imugene Limited
Novartis
Ascendis Pharma A/S
Tizona Therapeutics, Inc
Werewolf Therapeutics, Inc.
Prelude Therapeutics
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
Riboscience, LLC.
Sairopa B.V.
NovoCure Ltd.
Akamis Bio
Jazz Pharmaceuticals
Synthorx, Inc, a Sanofi company
VM Oncology, LLC
InSilico Medicine Hong Kong Limited
Erasca, Inc.
Transgene
BioInvent International AB
Eikon Therapeutics
Eikon Therapeutics
Incyte Corporation
Merck Sharp & Dohme LLC
NovoCure Ltd.
Eisai Inc.
Incyte Corporation
Hummingbird Bioscience
TuHURA Biosciences, Inc.